Derek-Zhen Xu

7.2k total citations
6 papers, 171 citations indexed

About

Derek-Zhen Xu is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Derek-Zhen Xu has authored 6 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hepatology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Derek-Zhen Xu's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Advanced Breast Cancer Therapies (1 paper). Derek-Zhen Xu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Advanced Breast Cancer Therapies (1 paper). Derek-Zhen Xu collaborates with scholars based in China, France and Taiwan. Derek-Zhen Xu's co-authors include Ann‐Lii Cheng, Shukui Qin, Hui Shao, Sairy Hernandez, Sohail Mulla, Yin‐Hsun Feng, Andrew X. Zhu, Wendy Verret, Richard S. Finn and Haitao Zhao and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Liver Cancer.

In The Last Decade

Derek-Zhen Xu

6 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Derek-Zhen Xu China 5 124 91 47 32 31 6 171
Kazuki Maesaka Japan 7 138 1.1× 84 0.9× 45 1.0× 27 0.8× 43 1.4× 12 210
Mallory Makowsky United States 4 129 1.0× 108 1.2× 46 1.0× 42 1.3× 28 0.9× 4 167
Aibing Xu China 7 82 0.7× 74 0.8× 40 0.9× 16 0.5× 29 0.9× 10 179
Takashi Mineo Japan 4 70 0.6× 85 0.9× 21 0.4× 43 1.3× 24 0.8× 12 168
Magdalena Żotkiewicz United States 3 91 0.7× 68 0.7× 40 0.9× 14 0.4× 37 1.2× 7 162
Alexander Vasilyev Russia 2 196 1.6× 158 1.7× 61 1.3× 38 1.2× 66 2.1× 3 284
Erik Ramon‐Gil United Kingdom 3 72 0.6× 52 0.6× 35 0.7× 28 0.9× 20 0.6× 5 126
Katsumi Terashita Japan 7 77 0.6× 55 0.6× 32 0.7× 17 0.5× 39 1.3× 8 189
Roger Esteban-Fabró Spain 4 70 0.6× 61 0.7× 23 0.5× 18 0.6× 29 0.9× 8 152
Éric Assenat France 7 113 0.9× 83 0.9× 24 0.5× 12 0.4× 46 1.5× 18 167

Countries citing papers authored by Derek-Zhen Xu

Since Specialization
Citations

This map shows the geographic impact of Derek-Zhen Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derek-Zhen Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derek-Zhen Xu more than expected).

Fields of papers citing papers by Derek-Zhen Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derek-Zhen Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derek-Zhen Xu. The network helps show where Derek-Zhen Xu may publish in the future.

Co-authorship network of co-authors of Derek-Zhen Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Derek-Zhen Xu. A scholar is included among the top collaborators of Derek-Zhen Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derek-Zhen Xu. Derek-Zhen Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

6 of 6 papers shown
1.
2.
Qin, Shukui, Zhenggang Ren, Yin‐Hsun Feng, et al.. (2021). Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study. Liver Cancer. 10(4). 296–308. 81 indexed citations
3.
4.
Finn, Richard S., Shukui Qin, Masafumi Ikeda, et al.. (2020). Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 38(15_suppl). 4596–4596. 5 indexed citations
5.
6.
Finn, Richard S., Michel Ducreux, Shukui Qin, et al.. (2018). IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.. Journal of Clinical Oncology. 36(15_suppl). TPS4141–TPS4141. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuki Maesaka Breakdown of academic impact, for papers by Mallory Makowsky Breakdown of academic impact, for papers by Aibing Xu Breakdown of academic impact, for papers by Takashi Mineo Breakdown of academic impact, for papers by Magdalena Żotkiewicz Breakdown of academic impact, for papers by Alexander Vasilyev Breakdown of academic impact, for papers by Erik Ramon‐Gil Breakdown of academic impact, for papers by Katsumi Terashita Breakdown of academic impact, for papers by Roger Esteban-Fabró Breakdown of academic impact, for papers by Éric Assenat
Rankless by CCL
2026